SERO Serologicals (MM)

Serologicals Corporation (NASDAQ:SERO) today announced that it will present at the 24th Annual JPMorgan Healthcare Conference on January 9, 2006. Bud Ingalls, Vice President, Finance and Chief Financial Officer for Serologicals Corporation, will be making the presentation. It is scheduled at 10:00 a.m. (Pacific Time) at the Westin St. Francis, 335 Powell Street, San Francisco, California. The presentation will be webcast and can be accessed at http://equityconferences.jpmorgan.com on the day of the presentation, or through the Company's website at www.serologicals.com. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, California, Upstate Group, LLC, headquartered in Charlottesville, Virginia and Celliance Corporation, headquartered in Atlanta, Georgia. For more information, please visit our website: www.serologicals.com.